Trial Profile
A Study Evaluating the Efficacy of Degarelix as Neoadjuvant Androgen-Deprivation Therapy (ADT) followed by Radiation Therapy in Control of Acute Genitourinary Toxicity Associated with Radiation Therapy for Prostate Cancer Compared to Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 22 May 2018 New trial record
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association.